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Appetite regulation: Shedding new light on obesity
C.J. Billington and A.S. Levine
Several genes involved in the regulation of appetite and
energy metabolism have been cloned and characterized
recently. Each seems to form part of the complex
regulatory network, centred in the hypothalamus, that is
responsible for striking a balance between food intake
and energy expenditure.
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New information illuminating the potential causes of
obesity has been appearing rapidly, beginning with the
cloning, by Friedman’s group, of the mouse obese (ob)
gene, as reported in December 1994 [1]. Many reports on
related topics and other molecular biological approaches to
obesity have followed, particularly in the last several
months. These reports help to form a picture that places
regulatory elements in the brain — and particularly in the
hypothalamus — at the heart of the pathogenesis of
obesity. In this report we review these developments and
try to show the context in which they are informative.
Recent excitement, scientifically and popularly, began
with the sequencing of the ob gene [1]. The sequence was
found to code for a protein, named leptin, that is
expressed uniquely in adipose tissue and secreted into the
circulation; mutant copies of the gene were found in mice
with the obese phenotype. These observations accord with
the well-defined physiology of ob/ob mice, which have a
single-gene defect that causes (among other things) severe
obesity, voracious appetite, reduced basal energy expendi-
ture, insulin resistance, and diminished fertility. Coleman
had demonstrated in 1973 [2] that parabiotic crossing of
circulation between affected and normal mice resulted in
diminished food intake and weight loss in the affected
mouse. From these and other observations, it had long
been supposed that a circulating fat-derived factor was
deficient in ob/ob mice. 
With knowledge of the gene sequence, it became possible
to produce significant quantities of wild-type leptin
protein. Using such synthetic leptin, workers in three lab-
oratories verified the predictions derived from physiologi-
cal studies [3–5]. Thus, leptin injections reversed the
abnormal phenotype in affected ob/ob mice, resulting in
diminished appetite, increased energy expenditure,
restoration of normal insulin levels, and amelioration of
obesity. A recent report indicates that fertility can also be
normalized in ob/ob mice by leptin administration [6].
More significantly, leptin given to wild-type mice
decreased appetite and body weight [3–5], and this effect
was particularly potent when the leptin was delivered into
the cerebroventricular fluid [5]. This indicates that leptin
probably works by signaling fat status to the brain’s regu-
latory pathways. Subsequent reports provided evidence
that leptin binds to hypothalamic cell membranes [7], and
that leptin administration diminishes the content in the
hypothalamus of neuropeptide Y [7,8], one neurochemical
that seems to participate in the regulation of appetite and
energy metabolism within the brain. Leptin administra-
tion appears also to enhance sympathetic nervous activity,
and presumably thermogenesis in brown fat [9] — a func-
tion that would be predicted from the finding that leptin
reduces hypothalamic neuropeptide Y, given that the neu-
ropeptide itself suppresses brown-fat thermogenesis [10]. 
Following the studies of leptin, interest was heightened in
a related form of single-gene obesity in mice, that of the
db/db mutant. Parabiotic crossed-circulation experiments
had indicated that the db/db mouse is resistant to the
effects of the circulating factor presumed to be missing in
the ob/ob mouse [2,11] — that is, the factor now thought to
be leptin. Speculation that the gene defective in the db/db
mouse codes for the leptin receptor was confirmed by
three laboratories this year [12–14]. The leptin receptor
seems to be expressed at high concentrations in the hypo-
thalamus [12], and studies of the receptor further support
the importance of brain neural networks in the regulation
of energy metabolism and appetite.
Blood levels of leptin, which seem to form a signal from
adipose tissue to the brain, are increased in nearly every
form of obesity in animals [15,16] and humans [16–18], the
exception being the ob/ob mouse itself; no human has yet
been identified who has no leptin, reduced leptin levels or
ineffective leptin. There is strong evidence that the
degree of obesity (or the fat mass) is directly correlated
with serum leptin levels [16–18]. This correlation is now
widely interpreted as meaning that obesity is a condition
associated with leptin resistance.
High levels of leptin in obese humans might mean that the
fatter a person gets, the less sensitive they become to the
effects of their own leptin. Some experimental support for
this concept has been reported by Schwartz and colleagues
[8], who found that leptin transport across the blood–brain
barrier between the circulation and the hypothalamus was
diminished in fat animals with high leptin levels. Even so,
it is important to approach this issue with care, because
other explanations are possible. A serum leptin-binding
protein might reduce the free (and therefore effective)
leptin level. More importantly, leptin may be only one of
many signals received and integrated by the brain’s regula-
tory mechanisms. If this were the case, what appears to be
leptin resistance could instead be due to a predominance
of non-leptin signals, or a primary abnormality in the regu-
latory mechanisms themselves. Leptin may thus prove to
be a potent tool for examining the central regulatory mech-
anisms governing appetite and energy metabolism.
Another single-gene defect, tubby, which confers sensitivity
to diet-induced obesity in the mouse, has recently been
characterized at the molecular level [19,20]. Abnormal
splicing of the tubby transcript, so that it retains an intron,
appears to characterize the abnormal gene. The identity
and function of the normal tubby protein have yet to be
revealed, but it is known that the normal gene is abun-
dantly expressed in the hypothalamus [20]. It should now
be possible to produce the normal tubby protein syntheti-
cally and to determine its physiological effects. Expanding
on the neural localization and function of the tubby protein
may be useful in defining neural pathways that participate
in energy metabolism regulation. Drawing conclusions
about human obesity from single-gene animal conditions
must be done with great care, however, because nearly all
human obesity is polygenic. Although knowledge of the
biological mechanisms underlying obesity has been, and
will continue to be, expanded tremendously by recent dis-
coveries using mutant mice, the direct application of this
knowledge to humans is not possible as yet.
The insights that have come from the genetic obesities so
far appear to be squarely centred on the hypothalamus
(see Fig. 1). In studies of the hypothalamus itself, other
discoveries have put forward new candidate neurochemi-
cals for potential roles in the control of appetite and
energy metabolism. Many of these neurochemicals are
already known, and gathering evidence supporting and
defining their role in the neural network regulating energy
balance remains a work in progress. The predominant
facts are often that the neurochemical either increases or
decreases feeding, and that the neurochemical is found
somewhere in the hypothalamus [21]. How the neuro-
chemicals interact, and in some cases where they act, is
more than ever a focus of great interest. New neurochemi-
cals for which there is strong evidence of involvement in
the energy-regulatory neural network include glucagon-
like peptide 1 (GLP-1) and melanocyte-concentrating
hormone, while additional evidence verifying the satiating
role of cholecystokinin has also appeared (Fig. 1).
Because the sequence of GLP-1 is highly conserved phy-
logenetically and the peptide is found near its receptor in
the hypothalamus, Turton and colleagues [22] tested
GLP-1 for appetite-modulatory effects. They found that,
when given into the cerebral ventricles, GLP-1 suppresses
feeding and a GLP-1 antagonist increases feeding. The
feeding stimulation caused by neuropeptide Y, but not
that caused by fasting, was enhanced by co-administration
of the GLP-1 antagonist. In studies aimed at defining the
neural substrate for these responses, Turton and col-
leagues [22] found that GLP-1 induced neural activation,
as exemplified by c-fos gene expression, in the paraven-
tricular nucleus of the hypothalamus and in the central
nucleus of the amygdala. Considerable evidence impli-
cates both of these neural sites in the appetite/energy
metabolism neuroregulatory network.
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Figure 1
A simplified scheme of the relationships
between adipose tissue, hypothalamic centres
and behavioral changes in feeding and/or
energy expenditure, which depend on
circulating factors and neurochemicals as
discussed in the text. It is not yet clear to what
extent the effects of the hypothalamic
neurochemicals on behavior are direct or
inter-related. There are many other
neurochemicals and brain sites that
participate in the regulation of feeding and
energy metabolism that are not shown in the
figure. 
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Using differential display coupled to the polymerase chain
reaction, Qu and colleagues [23] compared the genes
expressed in the hypothalamus of homozygous ob/ob mice
with that in heterozygous ob/+ mice. One mRNA overex-
pressed in the ob/ob mice was a neuropeptide, melanocyte-
concentrating hormone. Although this peptide had not
been implicated in appetite regulation previously, the
investigators were able to show that central injection of the
peptide stimulated food intake. This study therefore pro-
vides new physiological information about appetite regula-
tion, but also illustrates the use of a valuable tool for
investigating hypothalamic gene expression and function. A
recent report [24] has extended the already well-developed
data supporting the role of the hormone cholecystokinin as
a mediator of satiety. In this report, a cholecystokinin-inac-
tivating peptidase was purified and found in cholecys-
tokinin-sensitive neurons. When the action of the
peptidase was inhibited, cholecystokinin was protected and
satiation was detectable in the treated animals.
The complicated nature of the neuroregulation of appetite
and energy metabolism is well illustrated by the essen-
tially normal phenotype of the neuropeptide Y ‘gene
knockout’ mouse [25]. Neuropeptide Y is a neurochemical
for which there is extensive evidence supporting a role in
these controls [26], including robust feeding increases and
thermogenesis decreases after neuropeptide Y is adminis-
tered into specific brain sites (see Fig. 1), and appropriate
changes in endogenous neuropeptide Y at arcuate and par-
aventricular hypothalamic nuclei after changes in energy
balance. The absence of an abnormality of energy metabo-
lism in the neuropeptide Y knockout mice may reflect the
lack of brain-site specificity in gene knockouts, as neu-
ropeptide Y is widely distributed in the neuroaxis and par-
ticipates in many functions (few of which are abnormal in
the knockout). A more intriguing possibility is that the
regulatory machinery is plastic and redundant, allowing
other mechanisms to compensate for the absence of neu-
ropeptide Y in the knockout mice.
The apparent significance of neuropeptide Y in energy
metabolism regulation is heightened by a newly described
neuropeptide Y receptor [27]. This new receptor, named
Y5 was found by expression-cloning from rat hypothala-
mus. The Y5 receptor sequence is quite different from
that of other neuropeptide Y receptors, and the pattern of
Y5 receptor activation by peptides related to neuropeptide
Y correlates well with the potency of these peptides in
stimulating feeding. The Y5 receptor is found principally
in the brain, and particularly in the paraventricular nucleus
of the hypothalamus, a location that is consistent with the
known actions of neuropeptide Y on food intake and
energy metabolism [10].
Many of the recent advances point to a role for the hypo-
thalamus in regulating appetite and energy metabolism.
We know, however, that it is not the whole hypothalamus
that serves this function. The hypothalamus is made up
of many cell populations, traditionally grouped into
nuclei. These nuclei can be thought of as nodes in net-
works which regulate not only energy metabolism, but
water metabolism, sex hormone levels, breathing, blood
pressure and many other basic autonomic functions.
Some of the hypothalamic nuclei appear more relevant in
energy metabolism regulation than others (although
many appear to have a role): the arcuate, paraventricular,
suprachiasmatic and dorsomedial, in particular. Further-
more, we know that there are functional connections in
the energy-metabolism regulatory network that link the
hypothalamus to other key brain structures involved in
autonomic regulation, such as the nucleus of the solitary
tract in the medulla [28]. The amygdala appears to partic-
ipate in the response to more than one neurochemical as
well [22,29]. Given this perspective, we can expect
further advances as we apply some of the powerful new
knowledge and techniques to more specific portions of
the hypothalamus and to other brain sites. The great
challenge facing us — made easier by recent develop-
ments — is to shine a light on the components of the reg-
ulatory neural network and discern how the components
functionally interact to regulate appetite and energy
metabolism.
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